List of Tables
    Table 1. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Trends
    Table 3. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Drivers
    Table 4. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Challenges
    Table 5. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Restraints
    Table 6. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Share by Player, 2017-2022
    Table 13. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer as of 2021)
    Table 15. Top Players of PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Pfizer Company Details
    Table 31. Pfizer Business Overview
    Table 32. Pfizer PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 33. Pfizer Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 34. Pfizer Recent Development
    Table 35. Gland Pharma Company Details
    Table 36. Gland Pharma Business Overview
    Table 37. Gland Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 38. Gland Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 39. Gland Pharma Recent Development
    Table 40. Accord Healthcare Company Details
    Table 41. Accord Healthcare Business Overview
    Table 42. Accord Healthcare PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 43. Accord Healthcare Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 44. Accord Healthcare Recent Development
    Table 45. Novartis Company Details
    Table 46. Novartis Business Overview
    Table 47. Novartis PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 48. Novartis Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 49. Novartis Recent Development
    Table 50. Glenmark Pharmaceuticals Company Details
    Table 51. Glenmark Pharmaceuticals Business Overview
    Table 52. Glenmark Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 53. Glenmark Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 54. Glenmark Pharmaceuticals Recent Development
    Table 55. Cipla Company Details
    Table 56. Cipla Business Overview
    Table 57. Cipla PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 58. Cipla Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 59. Cipla Recent Development
    Table 60. Dr Reddy's Laboratories Company Details
    Table 61. Dr Reddy's Laboratories Business Overview
    Table 62. Dr Reddy's Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 63. Dr Reddy's Laboratories Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 64. Dr Reddy's Laboratories Recent Development
    Table 65. Natco Pharma Company Details
    Table 66. Natco Pharma Business Overview
    Table 67. Natco Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 68. Natco Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 69. Natco Pharma Recent Development
    Table 70. Intas Pharmaceuticals Company Details
    Table 71. Intas Pharmaceuticals Business Overview
    Table 72. Intas Pharmaceuticals PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 73. Intas Pharmaceuticals Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 74. Intas Pharmaceuticals Recent Development
    Table 75. Panacea Biotec Company Details
    Table 76. Panacea Biotec Business Overview
    Table 77. Panacea Biotec PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 78. Panacea Biotec Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 79. Panacea Biotec Recent Development
    Table 80. Alkem Laboratories Company Details
    Table 81. Alkem Laboratories Business Overview
    Table 82. Alkem Laboratories PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 83. Alkem Laboratories Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 84. Alkem Laboratories Recent Development
    Table 85. Biocon Pharma Company Details
    Table 86. Biocon Pharma Business Overview
    Table 87. Biocon Pharma PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product
    Table 88. Biocon Pharma Revenue in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022) & (US$ Million)
    Table 89. Biocon Pharma Recent Development
    Table 90. Research Programs/Design for This Report
    Table 91. Key Data Information from Secondary Sources
    Table 92. Key Data Information from Primary Sources
List of Figures
    Figure 1. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Product Picture
    Figure 2. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size 2017-2028 (US$ Million)
    Figure 4. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size 2017-2028 (US$ Million)
    Figure 6. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share in Global 2017-2028
    Figure 7. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Report Years Considered
    Figure 8. Product Picture of Temsirolimus
    Figure 9. Product Picture of Everolimus
    Figure 10. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type in 2022 & 2028
    Figure 11. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2017-2028) & (US$ Million)
    Figure 12. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type (2017-2028)
    Figure 13. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type in 2022 & 2028
    Figure 14. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Type (2017-2028)
    Figure 16. Product Picture of Hospital
    Figure 17. Product Picture of Clinic
    Figure 18. Product Picture of Drug Center
    Figure 19. Product Picture of Other
    Figure 20. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application in 2022 & 2028
    Figure 21. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2017-2028) & (US$ Million)
    Figure 22. Global PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2017-2028)
    Figure 23. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application in 2022 & 2028
    Figure 24. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size by Application (2017-2028) & (US$ Million)
    Figure 25. United States PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Share by Application (2017-2028)
    Figure 26. North America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 27. U.S. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 28. Canada PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Europe PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 30. Germany PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. France PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. U.K. PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Italy PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Russia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 36. China PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Japan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. South Korea PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. India PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Australia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Taiwan PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Indonesia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Thailand PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Malaysia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Philippines PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Latin America PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 47. Mexico PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Brazil PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Argentina PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 51. Turkey PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. U.A.E PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Pfizer Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 55. Gland Pharma Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 56. Accord Healthcare Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 57. Novartis Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 58. Glenmark Pharmaceuticals Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 59. Cipla Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 60. Dr Reddy's Laboratories Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 61. Natco Pharma Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 62. Intas Pharmaceuticals Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 63. Panacea Biotec Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 64. Alkem Laboratories Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 65. Biocon Pharma Revenue Growth Rate in PI3K/AKT/mTor Pathway Inhibitors for Breast Cancer Business (2017-2022)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed